This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Choi, J.-H. Articles by Shin, W.-S. Search for Related Content PubMed PubMed Citation Articles by Choi, J.-H. Articles by Shin, W.-S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2003, p. 3704-3707, Vol. 47, No. 12
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.12.3704-3707.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Effect of Moxifloxacin on Production of Proinflammatory Cytokines from Human Peripheral Blood Mononuclear Cells

Division of Infectious Disease, Department of Internal Medicine,¹ Clinical Research Institute, College of Medicine, Catholic University of Korea, Seoul, Korea²

Received 24 March 2003/ Returned for modification 30 June 2003/ Accepted 8 September 2003

The effects of moxifloxacin, a new methoxyfluoroquinolone, on the production of proinflammatory cytokines from human peripheral blood mononuclear cells (PBMCs) were evaluated. Moxifloxacin inhibited the production of tumor necrosis factor alpha (TNF-) and/or interleukin-6 (IL-6) by PBMCs stimulated with lipopolysaccharide (LPS), lipoteichoic acid (LTA), and heat-killed bacteria in a concentration-dependent manner without cytotoxic effects. The addition of moxifloxacin reduced the population of cells positive for CD-14 and TNF- and for CD-14 and IL-6 among the LPS- or LTA-stimulated PBMCs. By Western blot analysis, moxifloxacin pretreatment reduced the degradation of IB in LPS-stimulated PBMCs. In conclusion, moxifloxacin could interfere with NF-B activation by inhibiting the degradation of IB and reduce the levels of production of proinflammatory cytokines.

This article has been cited by other articles:

• Pardillo, F. E. F., Burgos, J., Fajardo, T. T., Cruz, E. D., Abalos, R. M., Paredes, R. M. D., Andaya, C. E. S., Gelber, R. H. (2008). Powerful Bactericidal Activity of Moxifloxacin in Human Leprosy. Antimicrob. Agents Chemother. 52: 3113-3117 [Abstract] [Full Text]  
• Calbo, E., Alsina, M., Rodriguez-Carballeira, M., Lite, J., Garau, J. (2008). Systemic Expression of Cytokine Production in Patients with Severe Pneumococcal Pneumonia: Effects of Treatment with a {beta}-Lactam versus a Fluoroquinolone. Antimicrob. Agents Chemother. 52: 2395-2402 [Abstract] [Full Text]  
• Blau, H., Klein, K., Shalit, I., Halperin, D., Fabian, I. (2007). Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-{kappa}B activation in a cystic fibrosis epithelial cell line. Am. J. Physiol. Lung Cell. Mol. Physiol. 292: L343-L352 [Abstract] [Full Text]  
• Weiss, T., Shalit, I., Blau, H., Werber, S., Halperin, D., Levitov, A., Fabian, I. (2004). Anti-Inflammatory Effects of Moxifloxacin on Activated Human Monocytic Cells: Inhibition of NF-{kappa}B and Mitogen-Activated Protein Kinase Activation and of Synthesis of Proinflammatory Cytokines. Antimicrob. Agents Chemother. 48: 1974-1982 [Abstract] [Full Text]